



## **Impel NeuroPharma to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021**

November 8, 2021

SEATTLE, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system (CNS), today announced that management will host a live webcast on Monday, November 15, 2021 at 8:30 a.m. ET to report its third quarter 2021 financial results and provide a business update.

The conference call may be accessed by dialling 877-295-2648 (domestic) or 470-495-9487 (international) and referring to conference ID 8366131. A live webcast of the event will be available on the Investors section of the Impel NeuroPharma website at <https://investors.impelnp.com/>. A replay of the webcast and accompanying slides will be available on the Impel NeuroPharma website following the event.

### **About Impel NeuroPharma**

Impel NeuroPharma, Inc. is a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. Impel offers and is developing treatments that pair its proprietary Precision Olfactory Delivery (POD®) technology with well-established therapeutics. In addition to Trudhesa™ (dihydroergotamine mesylate) nasal spray, which is approved in the United States for the acute treatment of migraine with or without aura in adults, Impel is also developing INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson's disease.

### **Investor Relations:**

Christina Tartaglia  
Stern Investor Relations  
Phone: (1) 212-362-1200  
Email: [christina.tartaglia@sternir.com](mailto:christina.tartaglia@sternir.com)

### **Media Relations:**

Melyssa Weible  
Elixir Health Public Relations  
Phone: (1) 201-723-5805  
Email: [mweible@elixirhealthpr.com](mailto:mweible@elixirhealthpr.com)